Skip to Content

Triheptanoin Approval Status

  • FDA approved: No
  • Generic name: triheptanoin
  • Company: Ultragenyx Pharmaceutical Inc.
  • Treatment for: Glucose Transporter Type-1 Deficiency Syndrome

Triheptanoin is a synthetic triglyceride compound in development for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS).

Development Status and FDA Approval Process for triheptanoin

Apr 23, 2015Ultragenyx Granted Additional Orphan Drug Designations for Triheptanoin
Dec 17, 2013Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.